Nicardipine Versus Labetalol During Intubation
Information source: Seoul National University Bundang Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Patients Who Are Intubated for General Anesthesia; Endotracheal Intubation
Intervention: labetalol (Drug); nicardipine (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Seoul National University Bundang Hospital Overall contact:
Jung-Hee Ryu, Ph.D, Phone: 82-31-787-7497, Email: jinaryu@lycos.co.kr
Summary
The aim of this study was to compare the efficacy of nicardipine and labetalol in
attenuation of cardiovascular responses to endotracheal intubation.
Clinical Details
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention
Primary outcome: hemodynamic variables (systolic blood pressure, diastolic blood pressure and mean blood pressure, heart rate)
Eligibility
Minimum age: 20 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients scheduled for general anesthesia with endotracheal intubation
Exclusion Criteria:
- Patients with heart failure or coronary artery disease 2-3 degree atrio-ventricular
block or severe bradycardia (< 45 beats/min) asthma, bronchial spasm or chronic
obstructive pulmonary disease patients with anticipated difficult intubation
(Mallampati class III, IV) severe hepatic or renal dysfunction allergy or
contraindication to study medication
Locations and Contacts
Jung-Hee Ryu, Ph.D, Phone: 82-31-787-7497, Email: jinaryu@lycos.co.kr
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do 463-707, Korea, Republic of; Recruiting
Jung-Hee Ryu, Ph.D, Phone: 82-31-787-7497, Email: jinaryu@lycos.co.kr
Additional Information
Starting date: September 2009
Last updated: December 30, 2009
|
